Celcuity (NASDAQ:CELC) Stock Price Up 7.7% – Here’s Why

Celcuity, Inc. (NASDAQ:CELC) shares were up 7.7% during mid-day trading on Tuesday . The company traded as high as $111.84 and last traded at $111.7840. 1,098,396 shares were traded during trading, an increase of 7% from the average session volume of 1,029,468 shares. The stock had previously closed at $103.79.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity secured FDA approval for REVTORPYK, its first approved therapy and a potentially important milestone for future revenue growth. Article Title
• Positive Sentiment: Citizens JMP raised its price target on Celcuity to $177 and kept an outperform rating, signaling continued analyst confidence after the approval. Article Title
• Positive Sentiment: Several reports highlighted the approval as a meaningful precision-oncology win that could make Celcuity a more attractive takeover or partnership candidate. Article Title
• Neutral Sentiment: Management discussed commercial launch plans after the approval, keeping attention on execution, reimbursement, and how quickly the drug reaches patients. Article Title
• Negative Sentiment: Despite the FDA win, shares fell as investors worried about a delayed launch and possible tolerability concerns that could slow adoption. Article Title
• Negative Sentiment: Some coverage said rollout questions and commercialization timing overshadowed the approval, suggesting near-term volatility may continue. Article Title

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $157.00 target price on shares of Celcuity in a research note on Friday, May 15th. Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a report on Thursday, May 28th. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Craig Hallum reissued a “buy” rating and issued a $178.00 price objective on shares of Celcuity in a research report on Wednesday. Finally, Citizens Jmp raised their target price on shares of Celcuity from $160.00 to $177.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $155.18.

Celcuity Stock Performance

The firm’s fifty day moving average price is $109.87 and its 200 day moving average price is $111.05. The firm has a market cap of $4.46 billion, a P/E ratio of -23.46 and a beta of 0.16. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. Sell-side analysts expect that Celcuity, Inc. will post -3.69 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.33% of the company’s stock.

Hedge Funds Weigh In On Celcuity

A number of large investors have recently added to or reduced their stakes in CELC. Avoro Capital Advisors LLC purchased a new position in shares of Celcuity in the 4th quarter worth approximately $310,302,000. NEA Management Company LLC raised its stake in shares of Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares in the last quarter. State Street Corp lifted its position in Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after acquiring an additional 914,887 shares during the last quarter. UBS Group AG lifted its position in Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after acquiring an additional 769,891 shares during the last quarter. Finally, Deerfield Management Company L.P. acquired a new stake in Celcuity in the third quarter valued at approximately $36,236,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.